梓橦宫:收到苯甲酸利扎曲普坦胶囊药品再注册批准通知书

Core Viewpoint - The company has received approval from the Sichuan Provincial Drug Administration for the re-registration of Benzylpiperazine capsules, which is a positive development for the stability and continuity of its production and operational qualifications [1] Group 1 - The approved drug is in capsule form with a specification of 5mg [1] - The drug approval number is National Drug Approval Code H20060352, and its validity period extends until November 9, 2030 [1] - The re-registration approval is expected to have a positive impact on the company's related product production and operational qualifications [1]